A Phase IA, Open-Label, Multiple-Dose, Dose Escalation Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects with Indolent B-Cell Lymphoid Malignancies
- Opat, Stephen (Primary Chief Investigator (PCI))
Project: Research